Lava Therapeutics Bv Stock Price, News & Analysis

LAVA Therapeutics N.V. (Nasdaq: LVTX) has announced promising clinical data from its ongoing Phase 1/2a trials for LAVA-051 and LAVA-1207, focusing on hematologic malignancies and metastatic castration-resistant prostate cancer. LAVA-051 demonstrated a favorable safety profile and initial anti-tumor activity in patients with chronic lymphocytic leukemia and multiple myeloma. Similarly, initial data for LAVA-1207 indicated a favorable safety profile with signs of clinical activity, including stabilized or decreased PSA levels in heavily pre-treated patients. Financially, LAVA reported a strong balance sheet with cash and investments totaling $132.9 million, expected to sustain operations through 2026. Additionally, a license agreement with Seagen for LAVA-1223 provides $50 million upfront and up to $650 million in potential milestones.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Oliger brings over 30 years of experience in the biopharmaceutical industry, including senior leadership roles at Genentech. She is recognized for her expertise in oncology and has led significant product launches. The company also announced the departure of Stefan Luzi, Ph.D., from the board. LAVA focuses on its proprietary Gammabody™ platform for developing bispecific gamma-delta T cell engagers targeting various malignancies, with ongoing clinical studies for its lead candidate LAVA-051.

LAVA Therapeutics announced initial clinical data from its ongoing Phase 1/2a study of LAVA-1207 for treating therapy refractory metastatic castration-resistant prostate cancer (mCRPC). The results, presented at ASCO GU, show a favorable safety profile with no high-grade cytokine release syndrome. Preliminary signs of anti-tumor activity were noted, including stable disease in 8 out of 14 patients and PSA levels stabilizing or decreasing. The trial features a dose escalation up to 120 micrograms, with treatment duration ranging from 4 to 38 weeks.

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company, announced that its CEO, Stephen Hurly, will present at the 2023 SVB Securities Global Biopharma Conference.

The presentation is scheduled for February 16, 2023, from 1:00 p.m. to 1:30 p.m. EST. A webcast will be available on the company's investor relations page and archived for 90 days post-event.

LAVA focuses on developing its proprietary Gammabody™ platform to create bispecific gamma-delta T cell engagers for cancer treatment, with notable pipeline candidates including LAVA-051 and LAVA-1207.

LAVA Therapeutics N.V. (Nasdaq LVTX) has appointed Dr. Charles Morris as Chief Medical Officer, effective February 6, 2023, succeeding Benjamin Winograd. Dr. Morris brings over 25 years of oncology experience, having held leadership roles at various biotech firms, including Celyad Oncology and Radius Health. His expertise in advancing oncology products is expected to enhance LAVA's Gammabody™ platform, aimed at treating various cancers with bispecific gamma-delta T cell engagers. The company is currently enrolling patients in clinical studies for its lead candidate, LAVA-051, and is optimistic about its potential to transform cancer treatment.